Cross talk between ERα and Src signaling and its relevance to ER status and hormone responsiveness

Jun Sun, Wen Zhou, Zafar Nawaz, Joyce M Slingerland

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

While two thirds of breast cancers are ER positive and a majority of these are responsive to endocrine therapies, up to one third of newly diagnosed breast cancers lack detectable ER protein. ER negative breast cancers are thought to be resistance to endocrine therapy. Here we review several potential mechanisms underlying the ER negative status of these breast cancers. The role of cross-talk between ER and Src-activated signal transduction as a mediator of both ER proteolysis and ER transactivation is discussed. Src kinase is often activated in breast cancer. Liganded ER rapidly and transiently activates Src which phosphorylates ER. For a subset of ER-responsive promoters, ER phosphorylation by Src leads to enhanced ER binding to the promoter, increased interactions with E3 ubiquitin ligases, and rapid ER degradation, in a process in which ER activation is coupled to its degradation. Thus, the function of ER may not be solely dependent on the steady state levels of ER protein. A subset of ER negative breast cancers that have ER mRNA but lack detectable ER protein levels may ultimately prove to be responsive to estrogen. These observations may have broader implications for estrogen driven gene expression. Cells of estrogen responsive tissues (ovary, bone, brain and intestine) could have low ER protein levels, but retain responses to estrogen through estrogen driven ER proteolysis-coupled transcriptional activity.

Original languageEnglish (US)
Title of host publicationAdvances in Rapid Sex-Steroid Action: New Challenges and New Chances in Breast and Prostate Cancers
PublisherSpringer New York
Pages61-78
Number of pages18
Volume9781461417644
ISBN (Print)9781461417644, 1461417635, 9781461417637
DOIs
StatePublished - Aug 1 2012

Fingerprint

Hormones
Breast Neoplasms
Estrogens
Proteolysis
Proteins
Ubiquitin-Protein Ligases
src-Family Kinases
Transcriptional Activation
Intestines
Ovary
Signal Transduction
Phosphorylation
Gene Expression
Bone and Bones
Messenger RNA
Brain
Therapeutics

Keywords

  • Breast cancer
  • Estrogen receptor
  • Proteolysis
  • Signal transduction
  • Src kinase
  • Ubiquitin

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Sun, J., Zhou, W., Nawaz, Z., & Slingerland, J. M. (2012). Cross talk between ERα and Src signaling and its relevance to ER status and hormone responsiveness. In Advances in Rapid Sex-Steroid Action: New Challenges and New Chances in Breast and Prostate Cancers (Vol. 9781461417644, pp. 61-78). Springer New York. https://doi.org/10.1007/978-1-4614-1764-4_4

Cross talk between ERα and Src signaling and its relevance to ER status and hormone responsiveness. / Sun, Jun; Zhou, Wen; Nawaz, Zafar; Slingerland, Joyce M.

Advances in Rapid Sex-Steroid Action: New Challenges and New Chances in Breast and Prostate Cancers. Vol. 9781461417644 Springer New York, 2012. p. 61-78.

Research output: Chapter in Book/Report/Conference proceedingChapter

Sun, J, Zhou, W, Nawaz, Z & Slingerland, JM 2012, Cross talk between ERα and Src signaling and its relevance to ER status and hormone responsiveness. in Advances in Rapid Sex-Steroid Action: New Challenges and New Chances in Breast and Prostate Cancers. vol. 9781461417644, Springer New York, pp. 61-78. https://doi.org/10.1007/978-1-4614-1764-4_4
Sun J, Zhou W, Nawaz Z, Slingerland JM. Cross talk between ERα and Src signaling and its relevance to ER status and hormone responsiveness. In Advances in Rapid Sex-Steroid Action: New Challenges and New Chances in Breast and Prostate Cancers. Vol. 9781461417644. Springer New York. 2012. p. 61-78 https://doi.org/10.1007/978-1-4614-1764-4_4
Sun, Jun ; Zhou, Wen ; Nawaz, Zafar ; Slingerland, Joyce M. / Cross talk between ERα and Src signaling and its relevance to ER status and hormone responsiveness. Advances in Rapid Sex-Steroid Action: New Challenges and New Chances in Breast and Prostate Cancers. Vol. 9781461417644 Springer New York, 2012. pp. 61-78
@inbook{05ebc5d7973a45f4acf5ea9535d0a372,
title = "Cross talk between ERα and Src signaling and its relevance to ER status and hormone responsiveness",
abstract = "While two thirds of breast cancers are ER positive and a majority of these are responsive to endocrine therapies, up to one third of newly diagnosed breast cancers lack detectable ER protein. ER negative breast cancers are thought to be resistance to endocrine therapy. Here we review several potential mechanisms underlying the ER negative status of these breast cancers. The role of cross-talk between ER and Src-activated signal transduction as a mediator of both ER proteolysis and ER transactivation is discussed. Src kinase is often activated in breast cancer. Liganded ER rapidly and transiently activates Src which phosphorylates ER. For a subset of ER-responsive promoters, ER phosphorylation by Src leads to enhanced ER binding to the promoter, increased interactions with E3 ubiquitin ligases, and rapid ER degradation, in a process in which ER activation is coupled to its degradation. Thus, the function of ER may not be solely dependent on the steady state levels of ER protein. A subset of ER negative breast cancers that have ER mRNA but lack detectable ER protein levels may ultimately prove to be responsive to estrogen. These observations may have broader implications for estrogen driven gene expression. Cells of estrogen responsive tissues (ovary, bone, brain and intestine) could have low ER protein levels, but retain responses to estrogen through estrogen driven ER proteolysis-coupled transcriptional activity.",
keywords = "Breast cancer, Estrogen receptor, Proteolysis, Signal transduction, Src kinase, Ubiquitin",
author = "Jun Sun and Wen Zhou and Zafar Nawaz and Slingerland, {Joyce M}",
year = "2012",
month = "8",
day = "1",
doi = "10.1007/978-1-4614-1764-4_4",
language = "English (US)",
isbn = "9781461417644",
volume = "9781461417644",
pages = "61--78",
booktitle = "Advances in Rapid Sex-Steroid Action: New Challenges and New Chances in Breast and Prostate Cancers",
publisher = "Springer New York",

}

TY - CHAP

T1 - Cross talk between ERα and Src signaling and its relevance to ER status and hormone responsiveness

AU - Sun, Jun

AU - Zhou, Wen

AU - Nawaz, Zafar

AU - Slingerland, Joyce M

PY - 2012/8/1

Y1 - 2012/8/1

N2 - While two thirds of breast cancers are ER positive and a majority of these are responsive to endocrine therapies, up to one third of newly diagnosed breast cancers lack detectable ER protein. ER negative breast cancers are thought to be resistance to endocrine therapy. Here we review several potential mechanisms underlying the ER negative status of these breast cancers. The role of cross-talk between ER and Src-activated signal transduction as a mediator of both ER proteolysis and ER transactivation is discussed. Src kinase is often activated in breast cancer. Liganded ER rapidly and transiently activates Src which phosphorylates ER. For a subset of ER-responsive promoters, ER phosphorylation by Src leads to enhanced ER binding to the promoter, increased interactions with E3 ubiquitin ligases, and rapid ER degradation, in a process in which ER activation is coupled to its degradation. Thus, the function of ER may not be solely dependent on the steady state levels of ER protein. A subset of ER negative breast cancers that have ER mRNA but lack detectable ER protein levels may ultimately prove to be responsive to estrogen. These observations may have broader implications for estrogen driven gene expression. Cells of estrogen responsive tissues (ovary, bone, brain and intestine) could have low ER protein levels, but retain responses to estrogen through estrogen driven ER proteolysis-coupled transcriptional activity.

AB - While two thirds of breast cancers are ER positive and a majority of these are responsive to endocrine therapies, up to one third of newly diagnosed breast cancers lack detectable ER protein. ER negative breast cancers are thought to be resistance to endocrine therapy. Here we review several potential mechanisms underlying the ER negative status of these breast cancers. The role of cross-talk between ER and Src-activated signal transduction as a mediator of both ER proteolysis and ER transactivation is discussed. Src kinase is often activated in breast cancer. Liganded ER rapidly and transiently activates Src which phosphorylates ER. For a subset of ER-responsive promoters, ER phosphorylation by Src leads to enhanced ER binding to the promoter, increased interactions with E3 ubiquitin ligases, and rapid ER degradation, in a process in which ER activation is coupled to its degradation. Thus, the function of ER may not be solely dependent on the steady state levels of ER protein. A subset of ER negative breast cancers that have ER mRNA but lack detectable ER protein levels may ultimately prove to be responsive to estrogen. These observations may have broader implications for estrogen driven gene expression. Cells of estrogen responsive tissues (ovary, bone, brain and intestine) could have low ER protein levels, but retain responses to estrogen through estrogen driven ER proteolysis-coupled transcriptional activity.

KW - Breast cancer

KW - Estrogen receptor

KW - Proteolysis

KW - Signal transduction

KW - Src kinase

KW - Ubiquitin

UR - http://www.scopus.com/inward/record.url?scp=84949176471&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949176471&partnerID=8YFLogxK

U2 - 10.1007/978-1-4614-1764-4_4

DO - 10.1007/978-1-4614-1764-4_4

M3 - Chapter

SN - 9781461417644

SN - 1461417635

SN - 9781461417637

VL - 9781461417644

SP - 61

EP - 78

BT - Advances in Rapid Sex-Steroid Action: New Challenges and New Chances in Breast and Prostate Cancers

PB - Springer New York

ER -